Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Roche is jump­ing back in­to the GLP-1 space with a de­fin­i­tive merg­er agree­ment to ac­quire Car­mot Ther­a­peu­tics for $2.7 bil­lion up­front. The deal gives Roche con­trol of Car­mot’s meta­bol­ic drug pipeline, which com­pris­es three GLP-1 ag­o­nists for obe­si­ty and re­lat­ed co­mor­bidi­ties.

Un­der the terms of the merg­er, Car­mot’s eq­ui­ty hold­ers could al­so get mile­stone pay­ments of up to $400 mil­lion, ac­cord­ing to a Roche press re­lease. The Big Phar­ma will get ac­cess to the biotech’s three drug can­di­dates, in­clud­ing a lead Phase II-ready sub­cu­ta­neous GLP-1/GIP re­cep­tor ag­o­nist, dubbed CT-388, for obe­si­ty in pa­tients with and with­out type 2 di­a­betes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.